glimepiride + metformin + insulin glargine

This is a combination therapy consisting of three agents—glimepiride, metformin, and insulin glargine—used in the management of type 2 diabetes mellitus. Glimepiride is a sulfonylurea that stimulates pancreatic beta cells to release insulin and increases peripheral tissue sensitivity to insulin. Metformin is a biguanide that improves insulin sensitivity and decreases hepatic glucose production. Insulin glargine is a long-acting recombinant human insulin analog providing basal glycemic control for up to 24 hours or longer. The combination targets multiple pathophysiological defects in type 2 diabetes, resulting in improved glycemic control compared to dual therapies or monotherapy[1][2][8]. This regimen may be prescribed when oral agents alone are insufficient for glycemic management.

Other names

insulin glargine/glimepiride/metformin